Key Highlights

  • Phase 2 three-year data on EVX-01 combination therapy due at ESMO, October 23-27.
  • Earlier data showed 86% of vaccine targets triggered tumor-specific immune responses.
  • Combination with Keytruda produced a 75% objective response rate.
  • Merck shares trade near $127.5, with a market value of about $314.9 billion.

Merck & Company (NYSE: MRK) is set to present three-year Phase 2 data on its personalized cancer vaccine EVX-01, used in combination with KEYTRUDA (pembrolizumab) and OPDIVO (nivolumab), at the ESMO 2026 congress running October 23-27.

What Happened

The candidate is being studied in metastatic melanoma. Previously reported Phase 2 data, noted April 20, 2026, showed that 86% of EVX-01's personalized vaccine targets triggered tumor-specific immune responses in advanced melanoma patients.

That earlier data also showed durable two-year T-cell responses and a 75% objective response rate when EVX-01 was combined with KEYTRUDA.

Market Reaction

Merck, a large-cap pharmaceutical company valued at approximately $314.9 billion, traded near $127.5 per share, down $0.13, or 0.1%, according to the disclosed pipeline database.

The muted share movement reflects the scale of Merck's overall business relative to any single pipeline readout, even one with a scheduled presentation at a major oncology congress.

Outlook

The three-year follow-up data on EVX-01 in combination with KEYTRUDA and OPDIVO is scheduled to be shared at ESMO between October 23 and 27, 2026.

What is EVX-01?

EVX-01 is a personalized cancer vaccine being studied in metastatic melanoma, in combination with Merck's KEYTRUDA and OPDIVO.

What did earlier EVX-01 data show?

Phase 2 data noted April 20, 2026 showed 86% of vaccine targets triggered tumor-specific immune responses, with a 75% objective response rate in combination with KEYTRUDA.

When will Merck present the updated data?

Three-year Phase 2 data is scheduled for presentation at the ESMO 2026 congress, held October 23-27.